has been suggested the Meisenheimer complex decomposes
to an arylthioester which acts as an amine acylating agent.5
In the past, thioacids have been used in combination
with N-terminal dNBS amino acid methyl esters6 to form
glycosyl, peptidoglycosyl, and peptidyl amide linkages. We
recently investigated the coupling of thioacids with N-
glycosyl-2,4-dinitrobenzenesulfonamides to afford N-gly-
cosyl amides.7 Further, Crich et al. demonstrated a solu-
tion phase peptide synthesis using combinations of
electron-deficient peptidyl benzenesulfonamides capable
of reacting with peptidyl thioacids with differential
reactivity.5 Seeking to further expand this amidation reac-
tion involving peptidyl thioacids and electron-deficient
peptidyl benzenesulfonamides we were interested in devel-
oping an Fmoc-based SPPS of N-dNBS peptides to access
longer N-dNBS peptides. We also desired to ligate the
resulting N-peptidyl sufonamide with an SPPS-derived
peptidyl thioacid to demonstrate a mixed-phase synthesis
of peptides and glycopeptides using the chemistry. We
chose to work with a glycopeptide sequence based on a
MUC1 tandem repeat based on our interest in the target.8
MUC1 tandem repeats are a heavily glycosylated
sequences that are part of the MUC1 transmembrane
protein. Aberrant MUC1 glycoforms are associated
with cancers of epithelial origin and are relevant targets
for glycopeptide-based anticancer therapeutics.9ꢀ11 The
20 amino acid tandem repeat possesses several possible
glycosylation sites at the threonine and serine residues
found along the repeating sequence NH2-PDTRPAPG-
STAPPA14H15G16VTSA-COOH, and synthetic access
to pure forms of the individual MUC1 glycoforms is
desirable. We investigated ligation at the H15-G16 and
A14-H15 sites to evaluate the dNBSꢀthioacid coupling
strategy with the simultaneous presence of multiple
unprotected functional groups, such as imidazole, car-
boxyl, and hydroxyl in the MUC1 fragments to demon-
strate the chemoselectivity of the amidation.
into an SPPS as well. To begin our study, we performed a
screening of conditions potentially useful for introducing
2,4-dinitrobenzenesulfonyl chloride (dNBS-Cl) on NH2-
Ala-Wang resin. The combination of dichloromethane
and pyridine was found optimal for introducing the dNBS
group onto peptides in solution phase.6a On solid phase
however, increased equivalents of dNBS-Cl (4 equiv) were
required for completion of the sulfonation. Other condi-
tions that were explored included CH2Cl2ꢀDIEA, DMFꢀ
pyridine, DMFꢀDIEA, and CH2Cl2ꢀpyridineꢀDMAP
(0.1 equiv), but all appeared unsatisfactory. The sulfonyla-
tion took 4 h to reach completion, and the reaction
progress was monitored by a Kaiser test.13 The dNBS-
alanine was cleaved from the resin by TFA treatment to
give the dNBS-alanine as the primary product. It was
notable that the dNBS group was stable to the acidic
cleavage condtions. After the optimization of the sufona-
tion conditions, the synthesis of longer 2,4-dinitrobenze-
nesulfonyl peptides and glycopeptides was attempted. The
peptides were manually assembled on preloaded Wang
resin using Fmoc chemistry. Coupling of the amino acids
was accomplished using PyBOP, HOBt, and DIEA in
DMF. The dNBS group was installed in the last coupling
step using 4 equiv of dNBS-Cl and 10 equiv of pyridine in
dichloromethane.
Table 1. N-Peptidyl-2,4-dinitrobenzenesulfonamides
SPPS is a common method for procuring medium sized
peptide fragments, and the coupling of o- and p- nitroben-
zenesulfonyl groups to the N-terminus of a peptide bound
to a rink amide MBHA resin has been reported.12,13 Thus,
it seemed feasible that dNBS groups could be introduced
(5) Crich, D.; Sharma, I. Angew. Chem., Int. Ed. 2009, 48, 7591.
(6) (a) Crich, D.; Sana, K.; Guo, S. Org. Lett. 2007, 9, 4423. (b) Crich,
D.; Sasaki, K.; Rahaman, M. Y.; Bowers, A. A. J. Org. Chem. 2009, 74,
3886.
(7) Talan, R. S.; Sanki, A. K.; Sucheck, S. J. Carbohydr. Res. 2009,
344, 2048.
(8) Sarkar, S.; Lombardo, S. A.; Herner, D. N.; Talan, R. S.; Wall,
K. A.; Sucheck, S. J. J. Am. Chem. Soc. 2010, 132, 17236.
(9) Gendler, S. J.; Lancaster, C. A.; Taylor-Papadimitriou, J.; Duhig,
T.; Peat, N.; Burchell, J.; Pemberton, L.; Lalani, E.-N.; Wilson, D. J.
Biol. Chem. 1990, 265, 15286.
(10) Finn, O. J.; Jerome, K. R.; Henderson, R. A.; Pecher, G.;
Domemech, N.; Magarian-Blander, J.; Barratt-Boyes, S. M. Immunol.
Rev. 1995, 145, 61.
€
(11) Brossart, P.; Schneider, A.; Dill, P.; Schammann, T.; Grunebach,
€
F.; Wirths, S.; Kanz, L.; Buhring, H.-J.; Brugger, W. Cancer Res. 2001, 61,
6846.
(12) (a) Miller, S. C.; Scanlan, T. S. J. Am. Chem. Soc. 1997, 119,
2301. (b) Miller, S. C.; Scanlan, T. S. J. Am. Chem. Soc. 1998, 120, 2690.
(13) Chan, W. C.; White, P. D. In Fmoc Solid Phase Peptide Synth-
esis: A Practical Approach; Chan, W. C., White, P. D., Eds.; Oxford
University Press: New York, NY, 2000; Chapter 3, pp 42ꢀ76.
Org. Lett., Vol. 13, No. 19, 2011
5299